Prognosis of ovarian clear cell cancer compared with other epithelial cancer types: A population‑based analysis

Liu, Hong; Xu, Yanbo; Ji, Jiali; Dong, Rongrong; Qiu, Huiqing; Dai, Xiaolan

doi:10.3892/ol.2020.11252

Cited by 27 publications

(37 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…121 Ovarian CCC has a poor prognosis of all the epithelial ovarian cancers. 122 Immunohistochemical analysis showed HNF1B nuclear staining in clear cell carcinoma specimens but minimal nuclear staining in non-clear cell carcinoma specimens. HNF1B may be an excellent CCC-specific molecular marker.…”

Section: Cancermentioning

confidence: 96%

Hepatocyte nuclear factor 1 beta: A perspective in cancer

2021

View full text Add to dashboard Cite

Hepatocyte nuclear factors (HNFs) exist as an assembly of transcription factors that have a vital role in the expression regulation of genes pertaining to the liver. 1 Conversely, these transcription factors are not restricted to hepatocytes, their expression has been observed in other tissues. 2 There are four major families of HNFs namely HNF1, HNF3, HNF4 and HNF6. The HNF1 family members; HNF1-α/A and HNF-1β/B comprise a POU-homeodomain and bind to DNA as homodimers or heterodimers. 3 Hepatocyte nuclear factor 1B (HNF1B, TCF2) located on chromosome 17q12, 4 belongs to the family of Pit-1, Oct-1/2, UNC-86 (POU) homeodomain-comprising transcription factors (Figure 1). The POU domain is bipartite (POU H and POU S) and is comprised of two subunits separated by a short 15-55 amino acid (aa) non-conserved region. The protein contains three predominant functional

show abstract

Section: Cancermentioning

confidence: 96%

Hepatocyte nuclear factor 1 beta: A perspective in cancer

2021

View full text Add to dashboard Cite

show abstract

“…30 This poorer outcome for patients with advanced-stage clear cell carcinoma has been confirmed in a study based on SEER data. 32 Recurrence of clear cell carcinoma tends to occur at multiple sites, and Hogan et al reported that 38 of 61 patients with recurrent clear cell carcinoma (62%) had multiple-site recurrence involving pelvic, extrapelvic, intrathoracic, lymph node and cerebral/meningeal sites. 33 The prognosis of patients with recurrent clear cell carcinoma is poorer than that of patients with recurrent serous carcinoma.…”

Section: Reviewmentioning

confidence: 99%

Clear cell carcinoma of the ovary: a clinical and molecular perspective

Iida

Okamoto

Hollis

et al. 2020

Int J Gynecol Cancer

View full text Add to dashboard Cite

Clear cell carcinoma of the ovary has distinct biology and clinical behavior. There are significant geographical and racial differences in the incidence of clear cell carcinoma compared with other epithelial ovarian tumors. Patients with clear cell carcinoma are younger, tend to present at an early stage, and their tumors are commonly associated with endometriosis, which is widely accepted as a direct precursor of clear cell carcinoma and has been identified pathologically in approximately 50% of clear cell carcinoma cases. The most frequent and important specific gene alterations in clear cell carcinoma are mutations of AT-rich interaction domain 1A (ARID1A) (~50% of cases) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) (~50% cases). More broadly, subgroups of clear cell carcinoma have been identified based on C-APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) and C-AGE (age-related) mutational signatures. Gene expression profiling shows upregulation of hepatocyte nuclear factor 1-beta (HNF1β) and oxidative stress-related genes, and has identified epithelial-like and mesenchymal-like tumor subgroups. Although the benefit of platinum-based chemotherapy is not clearly defined it remains the mainstay of first-line therapy. Patients with early-stage disease have a favorable clinical outcome but the prognosis of patients with advanced-stage or recurrent disease is poor. Alternative treatment strategies are required to improve patient outcome and the development of targeted therapies based on molecular characteristics is a promising approach. Improved specificity of the histological definition of this tumor type is helping these efforts but, due to the rarity of clear cell carcinoma, international collaboration will be essential to design appropriately powered, large-scale clinical trials.

show abstract

“…The conventional tumor marker CA125 has long been used in the diagnosis of HGSC. It is elevated in 75.6% of serous carcinoma cases but in only 57.6% of OCCC cases 91 . Thus, CA125 is a poor marker for OCCC, with only a mildly elevated baseline value and a frequent incidence of false-negative results 9 , 92 .…”

Section: Tumor Markersmentioning

confidence: 92%

Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma

Zhu¹,

Xu²,

Zhang³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

Ovarian clear cell carcinoma (OCCC) is a special pathological type of epithelial ovarian carcinoma (EOC) and has a high prevalence in Asia without specific molecular subtype classification. Endometriosis is a recognized precancerous lesion that carries 3-fold increased risk of OCCC. Ovarian endometrioid carcinoma, which also originates from endometriosis, shares several features with OCCC, including platinum resistance and younger age at diagnosis. Patients with OCCC have about a 2.5 to 4 times greater risk of having a venous thromboembolism (VTE) compared with other EOC, and OCCC tends to metastasize through lymphatic vesicular and peritoneal spread as opposed to hematogenous metastasis. There is only mild elevation of the conventional biomarker CA125. Staging surgery or optimal cytoreduction combined with chemotherapy is a common therapeutic strategy for OCCC. However, platinum resistance commonly portends a poor prognosis, so novel treatments are urgently needed. Targeted therapy and immunotherapy are currently being studied, including PARP, EZH2, and ATR inhibitors combined with the synthetic lethality of ARID1A-dificiency, and MAPK/PI3K/HER2, VEGF/bFGF/PDGF, HNF1β, and PD-1/PD-L1 inhibitors. Advanced stage, suboptimal cytoreduction, platinum resistance, lymph node metastasis, and VTE are major prognostic predictors for OCCC. We focus on update pathogenesis, diagnostic methods and therapeutic approaches to provide future directions for clinical diagnosis and treatment of OCCC.

show abstract

Prognosis of ovarian clear cell cancer compared with other epithelial cancer types: A population‑based analysis

Cited by 27 publications

References 26 publications

Hepatocyte nuclear factor 1 beta: A perspective in cancer

Hepatocyte nuclear factor 1 beta: A perspective in cancer

Clear cell carcinoma of the ovary: a clinical and molecular perspective

Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma

Contact Info

Product

Resources

About